AANEM News Express

AANEM News Express

Science News: Childhood Amyotrophic Lateral Sclerosis Caused by Excess Sphingolipid Synthesis

10/20/2021
 
Submitted by: Hristelina Ilieva

Mohassel P, Donkervoort S, Lone MA, et al. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis [published online ahead of print, 2021 May 31]. Nat Med. 2021;10.1038

Summary: ALS is a devastating disease with poorly understood underlying pathophysiology. This article describes a rare cause of the early onset of motor neuron disease in children due to mutation in SPLTC1, a subunit of the SPT (serine palmitoyltransferase). SPT is a key enzyme in sphingolipid metabolism. Mammalian SPT belongs to the family of pyridoxal phosphate (vit B6) dependent alpha-oxoamine synthases. A mutant subunit was identified in children with this disorder. Children developed toe walking and spasticity starting around 4 years of age and lived from 5 to 20 years. This mutation causes overproduction of sphingolipids. Sphingosine levels could be normalized by silencing approaches. This represents a potential therapy for this group of patients.

Comments: Better understanding the underlying mechanisms of disease may lead to more effective treatments. ALS is a heterogenous disease with multiple known and unknown pathologic contributors. The role of sphingolipids in ALS pathology is largely unknown and may be of clinical benefit for many patient populations.


View Related News Stories:

  EducationScience NewsNSEB


Recent AANEM News

Remembering George Kraft, MD, MS

The American Clinical Neurophysiology Society to Hold Another Townhall Meeting of Clinical Neurophysiology, Epilepsy, and Neuromuscular Fellowship Program Directors

Science News: Amyotrophic Lateral Sclerosis and Noninvasive Positive Pressure Ventilatory Support: "Nasal Noninvasive Ventilation" or "Noninvasive Ventilatory Support"?

CMS Finalizes Updates to Physician Fee Schedule

Advocacy in Action: State Liaison Leads the Way for Patient Advocacy in Washington and Beyond





Advertisement

ABEM

Advertisement

Donate

Advertisement